Outlook Therapeutics, Inc. OTLK

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
31/100
Developing

Ranked against 712 peers in Biotechnology

About Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. … Full OTLK analysis →

Key strengths

  • ROIC Sustainably Above Peers ROIC at 99.5th percentile exceeds peers and WACC, demonstrating superior capital allocation.

Key risks

  • Commodity Pressure / Weak Differentiation Gross margin at 17.0th percentile with high volatility suggests weak pricing power or commoditized products.
  • Elevated Debt Risk Debt serviceability is weak (score 0.24), raising refinancing risk.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Weak
10
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where OTLK ranks in Biotechnology

Outlook Therapeutics, Inc. ranks #508 of 713 scored companies in Biotechnology by moat score — the top 71%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
504 ICUCW ICUCW 31/100 Developing
505 Onconetix, Inc. ONCO 31/100 Developing
506 Cabaletta Bio, Inc. CABA 31/100 Developing
507 Werewolf Therapeutics, Inc. HOWL 31/100 Developing
508 Outlook Therapeutics, Inc. OTLK 31/100 Developing
509 PLUS THERAPEUTICS, Inc. PSTV 31/100 Developing
510 RenovoRx, Inc. RNXT 31/100 Developing
511 Crinetics Pharmaceuticals, Inc. CRNX 30/100 Developing
512 Praxis Precision Medicines, Inc PRAX 30/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How OTLK scores on the Corporate Default defenses

Pricing Power

Score 10 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 19 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 22 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 71 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 18 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 20 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding OTLK's moat

What is Outlook Therapeutics, Inc.'s moat score?

Outlook Therapeutics, Inc. (OTLK) scores 31 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #508 of 713 scored companies in Biotechnology, the top 71%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Capital Efficiency (71/100) and its weakest is Pricing Power (10/100).

How does Outlook Therapeutics, Inc. compare with other Biotechnology companies?

Outlook Therapeutics, Inc. ranks #508 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Werewolf Therapeutics, Inc. (HOWL) at 31 just above it and PLUS THERAPEUTICS, Inc. (PSTV) at 30 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Outlook Therapeutics, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Outlook Therapeutics, Inc.?

The Corporate Default template measures 6 defenses, and OTLK scores: Pricing Power (10), Cost Advantage (19), Customer Stickiness (22), Capital Efficiency (71), Resilience (18), Scale & Market Position (20). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000